Tumor burden stabilization/regression and late conversion to CR with repeated dosing of durvalumab after JCAR014. (A) Spider plot of the change in the sum of the product of the perpendicular diameters of ≤6 target measurable nodes and extranodal sites (SPD) over time compared with the baseline prelymphodepletion according to best response at 3 months. ∗ represents patients with extranodal disease and no measurable target lesion. ‡ represents patients who converted to CR at 1 year. PET/CT (B) and immunohistochemistry (C) images at different timepoints in a patient with late conversion to CR with continued durvalumab despite evidence of CD19^– escape. Images were taken at original magnification ×40.